T cell TET2 disruption cuts the breaks on antitumor CAR T cell therapy

Trends Immunol. 2023 Jun;44(6):397-398. doi: 10.1016/j.it.2023.03.008. Epub 2023 Mar 21.

Abstract

Functional persistence of chimeric antigen receptor (CAR) T cells is required for sustaining an antitumor response. Recently, Jain et al. revealed that disruption of TET2 in CAR T cells resulted in antigen-independent CAR T cell hyperproliferation that enhanced tumor control in mice, highlighting the potential of epigenetic strategies to improve T cell-based cancer immunotherapy.

Keywords: CAR T cells; TET2; cancer immunotherapy; epigenetics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • DNA-Binding Proteins / genetics
  • Dioxygenases*
  • Immunotherapy / methods
  • Immunotherapy, Adoptive / methods
  • Mice
  • Neoplasms* / therapy
  • Receptors, Antigen, T-Cell / genetics
  • T-Lymphocytes

Substances

  • Receptors, Antigen, T-Cell
  • Tet2 protein, mouse
  • DNA-Binding Proteins
  • Dioxygenases